Concepedia

Design and optimization of potent, selective antagonists of Oxytocin

Alan D. Brown, Lindsay Brown, Dave Ellis, Nicholas Puhalo, Christopher R. Smith, Olga Wallace, Lesa Watson

Bioorganic & Medicinal Chemistry Letters · 2008 · 12 citations · 7 references

DOIFull text

Open access

Concepts

References

7

Highly active catalysts for the Suzuki coupling of aryl chlorides

Robin B. Bedford, Catherine S. J. Cazin · Chemical Communications · 2001 · 160 citations

, , +12

1-(((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo[2.2.1]heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperazine (L-368,899): An Orally Bioavailable, Non-Peptide Oxytocin Antagonist with Potential Utility for Managing Preterm Labor

Peter Williams, Paul Anderson, Richard G. Ball et al. · Journal of Medicinal Chemistry · 1994 · 92 citations · Full text

, , +14

Pyridyl-2,5-Diketopiperazines as Potent, Selective, and Orally Bioavailable Oxytocin Antagonists: Synthesis, Pharmacokinetics, and In Vivo Potency

Alan D. Borthwick, John Liddle, Dave E. Davies et al. · Journal of Medicinal Chemistry · 2012 · 89 citations · Full text

, , +12

1-[1-[4-[(N-Acetyl-4-piperidinyl)oxy]-2- methoxybenzoyl]piperidin-4-yl]-4H-3,1- benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.

Bradley V. Clineschmidt, Jill M. Erb, Roger Freidinger et al. · Journal of Medicinal Chemistry · 1995 · 56 citations · Full text

, , +7

2,5-Diketopiperazines as Potent, Selective, and Orally Bioavailable Oxytocin Antagonists. 2. Synthesis, Chirality, and Pharmacokinetics

Alan D. Borthwick, Dave E. Davies, Anne M. Exall et al. · Journal of Medicinal Chemistry · 2005 · 53 citations · Full text

, , +16